Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageWe are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. As of December 28, 2025, we employed approximately 11,000 employees.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Business segments
Q2 2026 · $325.6MThe company’s own SEC segment disclosure.
- Life Sciences$183.6M56%
- Diagnostics$142.0M44%
Revvity (RVTY) reported revenue of $730M in Q2 2026 (quarter ended July 5, 2026), up 1.3% from the same quarter a year earlier. That came with a gross margin of 57% and net income of $52M (7.1% of revenue). For the full year FY2025, revenue was $2.86B (+3.7% year on year) and net income $241M. Its largest segment in 2026-Q2 was Life Sciences at $184M, 56% of the disclosed total, just ahead of Diagnostics at 44%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #26 of 29 by Smart Score